CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas

Shuodan Zhang, Byram H Ozer, Antonio Omuro, Ying Yuan, Tito Mendoza, Kathleen Wall, Eva Grajkowska, Elizabeth Vera, Jennifer Reyes, Kenneth Aldape, Marta Penas-Prado, Jing Wu, Eric C Burton, Tobias Walbert, Tom Mikkelsen, Shiao-Pei Weathers, Barbara O’Brien, John de Groot, Vinay Puduvalli, Lisa DeAngelis, Elena Pentsova, Thomas J Kaley, Igor Gavrilovic, Elizabeth R Gerstner, Terri S Armstrong, Mark R Gilbert

Open source

DOI: 10.1093/noajnl/vdag016
Published: 2026-01
Container: Neuro-Oncology Advances
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/noajnl/vdag016,
  title = {CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas},
  author = {Shuodan Zhang and Byram H Ozer and Antonio Omuro and Ying Yuan and Tito Mendoza and Kathleen Wall and Eva Grajkowska and Elizabeth Vera and Jennifer Reyes and Kenneth Aldape and Marta Penas-Prado and Jing Wu and Eric C Burton and Tobias Walbert and Tom Mikkelsen and Shiao-Pei Weathers and Barbara O’Brien and John de Groot and Vinay Puduvalli and Lisa DeAngelis and Elena Pentsova and Thomas J Kaley and Igor Gavrilovic and Elizabeth R Gerstner and Terri S Armstrong and Mark R Gilbert},
  year = {2026},
  journal = {Neuro-Oncology Advances},
  doi = {10.1093/noajnl/vdag016},
  url = {https://doi.org/10.1093/noajnl/vdag016}
}

RIS

TY  - JOUR
TI  - CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas
AU  - Shuodan Zhang
AU  - Byram H Ozer
AU  - Antonio Omuro
AU  - Ying Yuan
AU  - Tito Mendoza
AU  - Kathleen Wall
AU  - Eva Grajkowska
AU  - Elizabeth Vera
AU  - Jennifer Reyes
AU  - Kenneth Aldape
AU  - Marta Penas-Prado
AU  - Jing Wu
AU  - Eric C Burton
AU  - Tobias Walbert
AU  - Tom Mikkelsen
AU  - Shiao-Pei Weathers
AU  - Barbara O’Brien
AU  - John de Groot
AU  - Vinay Puduvalli
AU  - Lisa DeAngelis
AU  - Elena Pentsova
AU  - Thomas J Kaley
AU  - Igor Gavrilovic
AU  - Elizabeth R Gerstner
AU  - Terri S Armstrong
AU  - Mark R Gilbert
PY  - 2026
JO  - Neuro-Oncology Advances
DO  - 10.1093/noajnl/vdag016
UR  - https://doi.org/10.1093/noajnl/vdag016
ER  -

APA

Zhang, S., Ozer, B. H., Omuro, A., Yuan, Y., Mendoza, T., Wall, K., Grajkowska, E., Vera, E., Reyes, J., Aldape, K., Penas-Prado, M., Wu, J., Burton, E. C., Walbert, T., Mikkelsen, T., Weathers, S., O’Brien, B., Groot, J. D., Puduvalli, V., DeAngelis, L., Pentsova, E., Kaley, T. J., Gavrilovic, I., Gerstner, E. R., Armstrong, T. S., & Gilbert, M. R. (2026). CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdag016

Source records

crossref · retrieved 2026-09-25T18:15:46.574Z